News
Lilly's Mounjaro demonstrates cardiovascular protection
US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.
A WOMAN who has lost 5.5 stone on Mounjaro in eight months has shared the advice everyone needs to hear. La Hauser, from the ...
Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...
A YOUNG woman has revealed that in 14 weeks, she has lost three stone on Mounjaro. But although Jess now feels “healthier” ...
Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...
A primary school teacher who weighed 24 stone and was terrified of fitting on a plane said jabs which helped her lose weight ...
A WOMAN has revealed the awful side effects she has experienced when drinking on Mounjaro. Since becoming available on the ...
"The Mounjaro (tirzepatide) Patient Information Leaflet warns that hair loss is a common side effect in patients treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback